27
The ESMO Immuno Oncology Congress 2017 took place in Geneva, Switzerland, from 7-10 December 2017. Oncologists today must adapt to rapid changes in practice. The promising results of immunotherapies in oncology are generating increasing interest from the oncology community and have the potential to become the standard of care. This year, ESMO had launched the ESMO Immuno Oncology Congress, the new highly-focused meeting devoted entirely to the development and use of immunotherapies against cancer. The Congress gathered 926 participants from 53 countries I.e. 72,09% Europe, 12.2% North America, 10.4% Asia, 3.84% South America, 1.02% Africa and 0.45% Australia.

The ESMO Immuno Oncology Congress 2017, was attended by our two representatives; Andi Utama, Ph.D and Teguh Pribadi Putra, M.Biomed. In this event, research team from SCI submitted an abstract and participated as poster presenter. We shared the results of our research in colorectal cancer, which was a collaborative research between SCI and Rumah Sakit Medistra (Prof. dr. Antonius Nikolas Kurniawan, Sp.PA (K), Prof. Dr. dr. Aru Wisaksono Sudoyo, Sp.PD-KHOM, FACP and dr. Fritzie Rexana). The poster was presented by Teguh Pribadi Putra, entitled ”Association of PDL1 expression with TP53, KRAS mutation, and microsatellite instability in Indonesian patients with colorectal cancer ”. Importantly, our poster had been chosen to get travel grant (free registration and free accommodation) by ESMO Immuno Oncology Committee, because our research was very relevant with the theme of Immuno Oncology Congress and person who submitted the abstract must be as the first author and under 40 years old.


Figure 1. SCI attended ESMO Immuno Oncology Congress 2017, Teguh Pribadi Putra M.Biomed (Research Assistant)



Post Rating

Comments

There are currently no comments, be the first to post one.

Post Comment

Only registered users may post comments.

News & Events

SCAN

Events

SCI - Events

Stem Cell News

Cell Therapy News

Cancer News